SANGAMO THERAPEUTICS, INC (SGMOQ): Completion of Acquisition or Disposition of Assets
SANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. SANGAMO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 26-10989 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 07/31/2026 Petition Date: 06/23/2
How this was made
The 30-second read
Why it matters
The disclosure confirms ongoing bankruptcy restructuring with no asset sales, indicating continued financial distress and likely further share dilution.
Market read
Primary disclosure of bankruptcy details; limited trading impact but important for distressed‑asset investors.
What to watch
Potential for a buyer to acquire assets at a discount, which could create upside for remaining equity holders.
Background
Sangamo Therapeutics filed an 8‑K detailing its Chapter 11 monthly operating report, including cash balances, liabilities, and lack of asset sale proceeds.
Ticker impact
SEC Form 8‑K reports completion of acquisition or disposition of assets for Sangamo Therapeutics, a bankruptcy filing with detailed financials.
Downward pressure as investors reassess valuation amid bankruptcy proceedings.
Primary source filing provides new data, but the scale is limited to a distressed micro‑cap with no immediate cash proceeds.
Market effects
Highlights ongoing stress in the biotech/biopharma sector and may prompt scrutiny of other distressed pharma firms.
Limited to US OTC market; minimal broader regional effect.
Low global relevance; primarily affects niche investors in the company.
Counterpoint
If the asset sale yields unexpected cash, the stock could rally on restructuring optimism.
Key entities
- CompanySangamo Therapeutics, Inc.
Biopharma company in Chapter 11 bankruptcy.
- IndividualNikunj Jain
Responsible party signing the filing.
